BACKGROUND:Folic acid, vitamin B(6), and vitamin B(12) act in concert in the one-carbon metabolism and may protect against colorectal neoplasia. We examined the effect of combined B-vitamin treatment on the occurrence of colorectal adenoma. METHODS: The Women's Antioxidant and Folic Acid Cardiovascular Study was a randomized, double-blind, placebo-controlled trial of 5442 female health professionals at high risk for cardiovascular disease from April 1998 through July 2005. Participants were randomly assigned to receive a combination pill of folic acid (2.5mg), vitamin B(6) (50mg), and vitamin B(12) (1mg) or placebo. This study included 1470 participants who were followed up for as long as 9.2 years and underwent an endoscopy at any point during follow-up. We estimated relative risks using a generalized linear model with a natural logarithm link function and Poisson distributed errors. All statistical tests were two-sided. RESULTS: The risk of colorectal adenoma was similar among participants receiving treatment (24.3%, 180 of 741 participants) vs placebo (24.0%, 175 of 729 participants) (multivariable adjusted relative risk = 1.00, 95% confidence interval = 0.83 to 1.20). Treatment was not associated with the risk of adenoma when data were analyzed by subsite, size, stage, and the number of adenomas. There was no statistically significant effect modification by alcohol intake, history of cancer or adenoma, or baseline plasma levels or intakes of folate, vitamin B(6), or vitamin B(12). CONCLUSION: Our results indicate no statistically significant effect of combined folic acid, vitamin B(6), and vitamin B(12) treatment on colorectal adenoma among women at high risk for cardiovascular disease.
RCT Entities:
BACKGROUND:Folic acid, vitamin B(6), and vitamin B(12) act in concert in the one-carbon metabolism and may protect against colorectal neoplasia. We examined the effect of combined B-vitamin treatment on the occurrence of colorectal adenoma. METHODS: The Women's Antioxidant and Folic Acid Cardiovascular Study was a randomized, double-blind, placebo-controlled trial of 5442 female health professionals at high risk for cardiovascular disease from April 1998 through July 2005. Participants were randomly assigned to receive a combination pill of folic acid (2.5mg), vitamin B(6) (50mg), and vitamin B(12) (1mg) or placebo. This study included 1470 participants who were followed up for as long as 9.2 years and underwent an endoscopy at any point during follow-up. We estimated relative risks using a generalized linear model with a natural logarithm link function and Poisson distributed errors. All statistical tests were two-sided. RESULTS: The risk of colorectal adenoma was similar among participants receiving treatment (24.3%, 180 of 741 participants) vs placebo (24.0%, 175 of 729 participants) (multivariable adjusted relative risk = 1.00, 95% confidence interval = 0.83 to 1.20). Treatment was not associated with the risk of adenoma when data were analyzed by subsite, size, stage, and the number of adenomas. There was no statistically significant effect modification by alcohol intake, history of cancer or adenoma, or baseline plasma levels or intakes of folate, vitamin B(6), or vitamin B(12). CONCLUSION: Our results indicate no statistically significant effect of combined folic acid, vitamin B(6), and vitamin B(12) treatment on colorectal adenoma among women at high risk for cardiovascular disease.
Authors: Jung Eun Lee; Walter C Willett; Charles S Fuchs; Stephanie A Smith-Warner; Kana Wu; Jing Ma; Edward Giovannucci Journal: Am J Clin Nutr Date: 2011-01-26 Impact factor: 7.045
Authors: Regan L Bailey; Jaime J Gahche; Cindy V Lentino; Johanna T Dwyer; Jody S Engel; Paul R Thomas; Joseph M Betz; Christopher T Sempos; Mary Frances Picciano Journal: J Nutr Date: 2010-12-22 Impact factor: 4.798
Authors: C M Ulrich; E Kampman; J Bigler; S M Schwartz; C Chen; R Bostick; L Fosdick; S A Beresford; Y Yasui; J D Potter Journal: Cancer Epidemiol Biomarkers Prev Date: 1999-08 Impact factor: 4.254
Authors: Jane C Figueiredo; Leila A Mott; Edward Giovannucci; Kana Wu; Bernard Cole; Matthew J Grainge; Richard F Logan; John A Baron Journal: Int J Cancer Date: 2011-04-01 Impact factor: 7.396
Authors: A J Levine; K D Siegmund; C M Ervin; A Diep; E R Lee; H D Frankl; R W Haile Journal: Cancer Epidemiol Biomarkers Prev Date: 2000-07 Impact factor: 4.254
Authors: Shari S Bassuk; Christine M Albert; Nancy R Cook; Elaine Zaharris; Jean G MacFadyen; Eleanor Danielson; Martin Van Denburgh; Julie E Buring; Joann E Manson Journal: J Womens Health (Larchmt) Date: 2004 Jan-Feb Impact factor: 2.681
Authors: Rowena Chau; Seyedeh Ghazaleh Dashti; Driss Ait Ouakrim; Daniel D Buchanan; Mark Clendenning; Christophe Rosty; Ingrid M Winship; Joanne P Young; Graham G Giles; Finlay A Macrae; Alex Boussioutas; Susan Parry; Jane C Figueiredo; A Joan Levine; Dennis J Ahnen; Graham Casey; Robert W Haile; Steven Gallinger; Loïc Le Marchand; Stephen N Thibodeau; Noralane M Lindor; Polly A Newcomb; John D Potter; John A Baron; John L Hopper; Mark A Jenkins; Aung Ko Win Journal: Int J Epidemiol Date: 2016-04-10 Impact factor: 7.196
Authors: Jun Wang; Isaac Asante; John A Baron; Jane C Figueiredo; Robert Haile; A Joan Levine; Polly A Newcomb; Allyson S Templeton; Fredrick R Schumacher; Stan G Louie; Graham Casey; David V Conti Journal: Genet Epidemiol Date: 2019-09-10 Impact factor: 2.135